Alyeska Investment Group LP Has Lifted Biomarin Pharmaceutical (BMRN) Position By $3.47 Million; Horizon Pharma Plc Ord Ireland (HZNP) Shorts Decreased By 0.16%

December 8, 2017 - By Vivian Currie

Alyeska Investment Group Lp increased Biomarin Pharmaceutical Inc (BMRN) stake by 5.52% reported in 2017Q2 SEC filing. Alyeska Investment Group Lp acquired 38,564 shares as Biomarin Pharmaceutical Inc (BMRN)’s stock declined 0.71%. The Alyeska Investment Group Lp holds 736,721 shares with $66.91M value, up from 698,157 last quarter. Biomarin Pharmaceutical Inc now has $14.54 billion valuation. The stock increased 2.36% or $1.91 during the last trading session, reaching $82.81. About 392,641 shares traded. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has risen 5.29% since December 8, 2016 and is uptrending. It has underperformed by 11.41% the S&P500.

Horizon Pharma Plc Ord Ireland (NASDAQ:HZNP) had a decrease of 0.16% in short interest. HZNP’s SI was 14.73M shares in December as released by FINRA. Its down 0.16% from 14.76 million shares previously. With 1.90 million avg volume, 8 days are for Horizon Pharma Plc Ord Ireland (NASDAQ:HZNP)’s short sellers to cover HZNP’s short positions. The SI to Horizon Pharma Plc Ord Ireland’s float is 9.7%. The stock increased 1.58% or $0.23 during the last trading session, reaching $14.78. About 843,729 shares traded. Horizon Pharma Public Limited Company (NASDAQ:HZNP) has declined 28.13% since December 8, 2016 and is downtrending. It has underperformed by 44.83% the S&P500.

Investors sentiment decreased to 0.92 in 2017 Q2. Its down 0.10, from 1.02 in 2017Q1. It turned negative, as 43 investors sold Horizon Pharma Public Limited Company shares while 52 reduced holdings. 34 funds opened positions while 53 raised stakes. 130.94 million shares or 1.72% less from 133.24 million shares in 2017Q1 were reported. Morgan Stanley invested 0% in Horizon Pharma Public Limited Company (NASDAQ:HZNP). Cornerstone Holdings Limited Company owns 67,700 shares. Ahl Prtnrs Llp holds 36,012 shares. Armistice Ltd reported 1.24% in Horizon Pharma Public Limited Company (NASDAQ:HZNP). United Cap Financial Advisers Lc holds 0% or 37,009 shares in its portfolio. Pittenger & Anderson reported 1,500 shares or 0% of all its holdings. Redwood Ltd holds 505,590 shares. Broadfin Capital Ltd Liability Corp reported 4.06M shares. Segall Bryant And Hamill Limited Liability Com owns 0.17% invested in Horizon Pharma Public Limited Company (NASDAQ:HZNP) for 591,474 shares. Goldman Sachs Group Inc has invested 0.01% in Horizon Pharma Public Limited Company (NASDAQ:HZNP). Regions Financial has invested 0.01% in Horizon Pharma Public Limited Company (NASDAQ:HZNP). Teacher Retirement Of Texas has invested 0% in Horizon Pharma Public Limited Company (NASDAQ:HZNP). Vanguard Group Inc holds 0.01% or 12.98 million shares. Citigroup Inc owns 2.58 million shares. Moreover, Manufacturers Life Co The has 0% invested in Horizon Pharma Public Limited Company (NASDAQ:HZNP) for 125,933 shares.

Horizon Pharma Public Limited Company, a biopharmaceutical company, engages in identifying, developing, acquiring, and commercializing medicines for the treatment of orphan diseases, arthritis, pain, and inflammation and inflammatory diseases in the United States and internationally. The company has market cap of $2.42 billion. The companyÂ’s marketed medicine portfolio consists of ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; RAVICTI and BUPHENYL/AMMONAPS to treat urea cycle disorders; PROCYSBI for the treatment of nephropathic cystinosis; QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients; and KRYSTEXXA to treat chronic refractory gout. It currently has negative earnings. The Company’s products also include RAYOS/LODOTRA for the treatment of rheumatoid arthritis, polymyalgia rheumatic, systemic lupus erythematosus, and multiple other indications; DUEXIS to treat signs and symptoms of osteoarthritis and rheumatoid arthritis; MIGERGOT for the treatment of vascular headache; PENNSAID 2% to treat pain of osteoarthritis of the knees; and VIMOVO for the treatment of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.

Among 13 analysts covering Horizon Pharma (NASDAQ:HZNP), 10 have Buy rating, 0 Sell and 3 Hold. Therefore 77% are positive. Horizon Pharma had 53 analyst reports since September 9, 2015 according to SRatingsIntel. The company was initiated on Wednesday, June 29 by BMO Capital Markets. Mizuho maintained Horizon Pharma Public Limited Company (NASDAQ:HZNP) rating on Tuesday, November 10. Mizuho has “Buy” rating and $34 target. The company was initiated on Tuesday, January 19 by Jefferies. The stock of Horizon Pharma Public Limited Company (NASDAQ:HZNP) earned “Buy” rating by BMO Capital Markets on Tuesday, September 26. Jefferies maintained the stock with “Buy” rating in Tuesday, November 7 report. The firm has “Mkt Outperform” rating given on Wednesday, September 9 by JMP Securities. The rating was maintained by Mizuho with “Buy” on Tuesday, November 8. The rating was maintained by Cowen & Co with “Buy” on Friday, November 10. The firm has “Hold” rating by Mizuho given on Monday, August 28. Piper Jaffray maintained it with “Buy” rating and $18.0 target in Friday, October 13 report.

Alyeska Investment Group Lp decreased Xylem Inc (NYSE:XYL) stake by 36,813 shares to 54,506 valued at $3.02 million in 2017Q2. It also reduced Oracle Corp (NYSE:ORCL) stake by 3.20M shares and now owns 66,128 shares. Euronav Nv Antwerpen was reduced too.

Since June 16, 2017, it had 0 insider purchases, and 2 selling transactions for $1.69 million activity. On Friday, June 16 the insider LAWLIS V BRYAN sold $337,500. Another trade for 15,000 shares valued at $1.35 million was made by FUCHS HENRY J on Friday, June 16.

Investors sentiment increased to 1.26 in 2017 Q2. Its up 0.06, from 1.2 in 2017Q1. It improved, as 23 investors sold BMRN shares while 124 reduced holdings. 51 funds opened positions while 134 raised stakes. 168.09 million shares or 1.78% more from 165.15 million shares in 2017Q1 were reported. Moreover, Brown Brothers Harriman And has 0% invested in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). 24,843 were accumulated by Oppenheimer Asset Mngmt Incorporated. Sivik Glob Healthcare Ltd Liability Com holds 2.83% or 85,000 shares in its portfolio. Captrust Fin Advsrs, a North Carolina-based fund reported 103 shares. Svcs Automobile Association has 0.01% invested in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) for 35,354 shares. 94,454 were accumulated by Blue Jay Mngmt. Victory Management Inc has 0.18% invested in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) for 856,915 shares. Apg Asset Mgmt Nv holds 0.01% or 53,880 shares. Moreover, Efg Asset (Americas) Corporation has 0.19% invested in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Clarivest Asset Management Ltd Company accumulated 10 shares. Cubist Systematic Strategies Lc invested in 6,038 shares or 0.04% of the stock. Emory University owns 17,330 shares. 244 are held by Winfield Assoc Incorporated. Viking Glob Invsts LP owns 259,656 shares or 0.16% of their US portfolio. New York-based Sg Americas Llc has invested 0% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com